M Pharmaceutical Inc.

M Pharmaceutical Inc.

September 03, 2015 11:36 ET

M Pharmaceutical Inc. Advises Shareholders on the Amendment of Terms and Pricing of Warrants

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 3, 2015) - M Pharmaceutical Inc. (CSE:MQ)(OTCQB:MPHMF) (FRANKFURT:T3F2 ) (the "Company"), a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications advises that the Company board of directors has resolved to reprice 1,100,000 warrants previously due to expire on September 13, 2015 ("September 2015 Warrants") and 330,000 warrants due to expire on February 25, 2016 ("February 2016 Warrants"). The exercise price of each of September 2015 Warrants and the February 2016 Warrants has been changed to C$ 0.13. Further, it was resolved to extend the expiry date of the September 2015 Warrants until the close of business (Vancouver B.C. local time) on October 31, 2015. The expiry date of the February 2016 Warrants has not been amended and will expire on February 25, 2016. No further amendments have been made to either the September 2015 Warrants or the February 2016 Warrants; all other terms and conditions, as detailed in the respective warrant certificates, remain in effect.

The Company will notify affected registered warrant holders by mail or by email. Original, paper warrant certificates will not be replaced. In order to exercise the September 2015 Warrants or the February 2016 Warrants, holders shall provide the original warrant certificates to the Company with a cheque in the amount of C$ 0.13 per exercised warrant prior to the applicable expiry date.

Matthew Lehman, the Company CEO stated: "I am pleased that the Company is able to amend the terms of existing warrants. I believe this will provide the Company capital to progress our development plans for Trimeo, Trimtec, and eMosquito."

About M Pharmaceutical Inc.

Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications. The Company has exclusive rights to three technologies: (1) Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity; (2) Trimtec, gastrointestinal neurostimulators implanted laparoscopically for the treatment of obesity and gastroparesis without permanent anatomical modification of the stomach; and (3) eMosquito wearable blood monitor, for automatic and autonomous monitoring of blood glucose by diabetics.

M Pharmaceutical trades on the Canadian Securities Exchange (CSE) under the ticker symbol "MQ" as well as on the OTCQB as "MPHMF" and FWB (Frankfurt Stock Exchange) as "T3F2."

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the eMosquito, Trimeo and Trimtec biomedical technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and the Company's filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: Trimeo, Trimtec, and eMosquito are investigational devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.

Contact Information